Study of those with severe #COVID19 finds “At 12 months of follow-up, 43% of patients presented with dyspnea, 27% of whom had a restrictive ventilatory disorder and 18% of whom presented with impaired DLCO (Diffusing capacity of the lungs for carbon monoxide).”
Paxlovid may have helped some who were not hospitalized, but this study of those hospitalized with #COVID19 found that "neither molnupiravir nor nirmatrelvir-ritonavir were associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death." (And Paxlovid can be associated with greater risk of viral mutations.)
New STUDY finds that those with #COVID19 have an 8x greater risk of acute respiratory complications or post-acute respiratory sequela. "Furthermore, while the excess post-acute risk diminished with time following SARS-CoV-2 infection, it persisted beyond 6 months post-infection. "